You are here:   Blog
Register   |  Login

The Wellness Blog with Elaine Moore

Blogs by Date

Elaine Moore's Blog
Elaine Moore
298 72254 5/8/2020

Blogs by Category

 

Main Blog

 
     

LDN and Ketamine COVID-19 Trial

By Elaine Moore on 5/8/2020

In severe cases of infection with the SARS-CoV-2 virus, the cause of COVID-19, an autoimmune reaction is responsible for deadly symptoms. In stages 2b, late pulmonary effects are seen, and in stage 3 hyperinflammation with cytokine storms occur.

Severe cases of this disease are associated with low lymphocyte counts and high levels of the cytokine, interleukin-6 (IL-6). As immunomodulators when used in low doses, both low dose naltrexone (LDN) and ketamine reduce IL-6 production, halting COVID-19 disease progression. In addition, LDN is known to have antiviral properties.

The trial, Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 (SINK COVID-19) is being conducted at William Beaumonts Hospitals and information on the trial can be found at https://clinicaltrials.gov/ct2/show/NCT04365985

Resource:

Elaine A. Moore and Samantha Wilkinson. The Promise of Low Dose Naltrexone. McFarland Publishing. 2009.

www.clinicaltrials.gov


READ MORE ABOUT LDN

 




Elaine-Moore.com   |   Elaine Moore Graves' Disease and Autoimmune Disease Education
Copyrighted by Elaine Moore © 2008-2020 All Rights Reserved. All writing and images copyrighted.
Copyright Notices and Disclaimer